Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

Loi, S; Karapetis, CS; McCarthy, N; Oakman, C; Redfern, A; White, M; Khasraw, M; Doval, DC; Gore, V; Alam, M; Binko, J; Lu, DR; Kim, S; Boyle, F

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

journal contribution

posted on 2024-06-13, 15:06 authored by S Loi, CS Karapetis, N McCarthy, C Oakman, A Redfern, M White, M Khasraw, DC Doval, V Gore, M Alam, J Binko, DR Lu, S Kim, F Boyle

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

History

Journal

Asia-Pacific Journal of Clinical Oncology

Pagination

1-10

Location

London, Eng.

Open access

Yes

Link to full text

http://doi.org/10.1111/ajco.13653

ISSN

1743-7555

eISSN

1743-7563

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Publisher

Wiley

Usage metrics

Keywords

advanced breast cancer Australia HR+/HER2-India letrozole palbociclib 3211 Oncology and carcinogenesis

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

History

Journal

Pagination

Location

Open access

Link to full text

ISSN

eISSN

Language

Publication classification

Publisher

Usage metrics

Categories

Keywords

Licence

Exports